Compare ECX & FLGT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ECX | FLGT |
|---|---|---|
| Founded | 2017 | 2011 |
| Country | China | United States |
| Employees | 1918 | N/A |
| Industry | EDP Services | Medical Specialities |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 560.1M | 867.4M |
| IPO Year | N/A | 2016 |
| Metric | ECX | FLGT |
|---|---|---|
| Price | $1.55 | $14.26 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $28.33 |
| AVG Volume (30 Days) | ★ 2.7M | 310.5K |
| Earning Date | 01-01-0001 | 06-01-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $18,730,000.00 |
| Revenue This Year | $825.35 | $12.64 |
| Revenue Next Year | $35.50 | $9.87 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.76 | $14.57 |
| 52 Week High | $3.25 | $31.04 |
| Indicator | ECX | FLGT |
|---|---|---|
| Relative Strength Index (RSI) | 42.58 | 15.95 |
| Support Level | $1.27 | N/A |
| Resistance Level | $1.77 | $19.96 |
| Average True Range (ATR) | 0.16 | 0.99 |
| MACD | -0.00 | -0.73 |
| Stochastic Oscillator | 9.74 | 2.02 |
ECARX Holdings Inc is engaged in the sales of system-on-chip core modules, automotive computing platform products, and software stacks as well as the provision of research and development services in the People's Republic of China. The company's core products include infotainment head units, digital cockpits, vehicle chip-set solutions, a core operating system, and an integrated software stack. Beyond this, ECARX is developing a full-stack automotive computing platform. It is engaged in automotive intelligence and networking.
Fulgent Genetics Inc is a technology company that focuses on genetic testing to provide physicians with clinically actionable diagnostic information. The company is engaged in laboratory services business and a therapeutic development business. The laboratory services business which generates key revenue includes, technical laboratory services and professional interpretation of laboratory results by licensed physicians. Its therapeutic development business is focused on developing drug candidates for treating a broad range of cancers. The geographical segments are the United States, which generates the vast majority of the revenue; and Foreign.